Background. Gandoufumu decoction (GDFMD) is a traditional Chinese medicine that has been widely used to treat Wilsons disease (WD) liver damage patients. However, its specific molecular mechanism currently remains unclear. Autophagy as a key contributor to WD liver damage has been intensely researched in the recent years. Therefore, the aim of this present study is to explore the effect of GDFMD on autophagy in WD liver damage, and the final purpose is to provide scientific evidence for GDFMD treatment in WD liver damage. Methods. The molecular mechanisms and autophagy-related pathways of GDFMD in the treatment of WD liver damage were predicted using network pharmacology. Copper assay kit was used to determine copper content in serum. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify serum levels of liver enzymes and oxidative stress-related indicators. Hematoxylin-eosin (HE), Masson, and Sirius red staining were used for the characterization of liver pathological changes. Transmission electron microscopy, immunofluorescence, and Western blot analyses were used to evaluate autophagy activity. The impact of the GDFMD on typical autophagy-related pathway (PI3K/Akt/mTOR pathway) molecules was also assessed via Western blot analysis. Results. GDFMD effectively attenuated serum liver enzymes, oxidative stress, autophagy, and degree of hepatic histopathological impairment and reduced serum copper content. Through network pharmacological approaches, PI3K/Akt/mTOR pathway was identified as the typical autophagy-related pathway of GDFMD in the treatment of WD liver damage. Treatment with GDFMD activated the PI3K/Akt/mTOR pathway, an effect that was able to be counteracted by LY294002, a PI3K antagonist or Rapa (rapamycin), an autophagy inducer. Conclusions. GDFMD imparted therapeutic effects on WD through autophagy suppression by acting through the PI3K/Akt/mTOR pathway.
Arboleda−Tham syndrome (ARTHS) is a rare disorder first characterized in 2015 and is caused by mutations in lysine (K) acetyltransferase 6A (KAT6A, a.k.a. MOZ, MYST3). Its clinical symptoms have rarely been reported in newborns from birth up to the first few months after birth. In this study, a newborn was diagnosed with ARTHS based on the clinical symptoms and a mutation c.3937G>A (p.Asp1313Asn) in KAT6A. The clinical manifestations, diagnosis, and treatment of the newborn with ARTHS were recorded during follow-up observations. The main symptoms of the proband at birth were asphyxia, involuntary breathing, low muscle tone, early feeding, movement difficulties, weak crying, weakened muscle tone of the limbs, and embrace reflex, and facial features were not obvious at birth. There was obvious developmental delay, as well as hypotonic and oro-intestinal problems in the first few months after birth. Mouse growth factor was used to nourish the brain nerves, and touching, kneading the back, passive movements of the limbs, and audio−visual stimulation were used for rehabilitation. We hope that this study expands the phenotypic spectrum of this syndrome to newborns and the library of KAT6A mutations that lead to ARTHS. Consequently, the data can be used as a basis for genetic counseling and in clinical and prenatal diagnosis for ARTHS prevention.
4 January 2022 in Evidence-Based Complementary and Alternative Medicine
Background. This study used a combination of network pharmacology and experimental confirmation to clarify the mechanism of the compound kidney-invigorating granule (CKG) in treating osteoporosis (OP). Methods. The main bioactive compounds and corresponding targets of CKG were collected and screened via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Yet another Traditional Chinese Medicine (YaTCM), and UniProt databases. Disease targets of OP were summarized in GeneCards and the Comparative Toxicogenomics Database (CTD). Targets of CKG for OP were obtained by Venn diagram. The protein-protein interaction (PPI) network was constructed by the STRING database and then screened for hub genes through Cytoscape 3.7.2 software. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were analyzed and visualized by R software. Then, CB-Dock was used for molecular docking verification. Finally, we confirmed the antiosteoporosis effect of CKG through animal and cell experiments. Results. A total of 250 putative targets were obtained from 65 bioactive compounds in CKG. Among them, 140 targets were related to OP. Topological analysis of the PPI network yielded 23 hub genes. Enrichment analysis showed the targets of CKG in treating OP might concentrate on the MAPK signaling pathway, the TNF signaling pathway, the PI3K-Akt signaling pathway, etc. The results of molecular docking showed the bioactive components in CKG had good binding ability with the key targets. The experimental results showed that CKG-medicated serum had a promoting effect on proliferating hBMSCs, increasing the expression of AKT, PI3K, ERK1, and IkB in cells and decreasing the expression of IKK in cells. Conclusion. CKG has a complex of multicomponent, multitarget, and multipathway. This study lays the theoretical foundation for further in vitro and in vivo experimental studies and further expands the clinical applications of CKG.
Various pathologies, environmental factors, and medications can cause anal distension. Sacrococcygeal chordoma is a rare tumor originating from the remnants of the primitive spinal cord. Nonetheless, only a few case reports of anal swelling caused by sacrococcygeal chordoma have been published. This article reports a female patient with a history of mastectomy due to breast cancer who presented with anal swelling and was finally diagnosed with sacrococcygeal chordoma. The patient experienced anal swelling and discomfort that worsened at night. A smooth, oval-shaped mass was palpable in the rectum, 4 cm from the anal verge near the coccyx. The mass was tender and no blood was found on the glove after examination. A mass shadow was observed in and around the S2-5 vertebrae according to MRI. Immunohistochemical analysis revealed strong positivity for vimentin(VIM), cytokeratin(CK) AE1/AE3, epithelial, embrane antigen(EMA), and S-100 protein. The cytogenetic marker SMARCB1/INI1 was positive but not missing, and the Ki-67 proliferation index was approximately 5%. These findings confirmed the diagnosis of sacrococcygeal chordoma. This article aims to expand the knowledge about sacrococcygeal chordoma and its pathogenesis. Notably, chordoma can exclusively cause anal swelling, and clinicians should consider differential diagnosis in practice.
Background: The imbalance between osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) is a key factor in osteoporosis (OP). TRIB3 acts as a molecular switch regulating this process. While E3 ubiquitin ligases are known to influence TRIB3 protein stability, the specific role of E3 ligase‐mediated TRIB3 ubiquitination in directing BMSCs’ fate remains unclear. This study systematically investigates this mechanism. Methods: We first predicted potential E3 ubiquitin ligases for TRIB3 using the UbiBrowser database. Differentially expressed E3 ligases were then screened from the GEO datasets. Molecular docking with the TRIB3 protein identified the candidate with the highest binding affinity for a mechanistic study. Serum samples from osteoporotic patients and healthy controls were analyzed to verify clinical correlation. For in vivo validation, we performed in vivo rescue experiments in naturally aged osteoporotic mice using femoral injection of SIAH1‐knockdown lentivirus. Immunohistochemistry, immunofluorescence, and western blot were used to assess the expression of TRIB3 and SIAH1. In vitro, we overexpressed or knocked down SIAH1 to examine its effects on TRIB3 ubiquitination, protein stability, and BMSCs differentiation. TRIB3 rescue assays were performed to confirm the dependency. Results: UbiBrowser analysis identified eight E3 ubiquitin ligases targeting TRIB3. Subsequent screening selected SIAH1 for mechanistic investigation. In aged osteoporotic mice and osteoporotic patients, SIAH1 expression was significantly increased, while TRIB3 was decreased. In vivo rescue experiments showed that local knockdown of SIAH1 restored TRIB3 expression, improved bone mineral density (BMD), trabecular microarchitecture, and rebalanced osteogenic and adipogenic differentiation. In vitro, upregulating SIAH1 promoted TRIB3 ubiquitination and proteasomal degradation, reducing TRIB3 protein levels, downregulating osteogenic markers, and upregulating adipogenic markers. Knocking down SIAH1 yielded the opposite effects. TRIB3 overexpression or knockdown fully reversed the effects of SIAH1 on BMSC differentiation. Conclusion: SIAH1 promotes the ubiquitination and proteasomal degradation of TRIB3, thereby disrupting the osteogenic–adipogenic balance of BMSCs and contributing to age‐related bone loss. Local inhibition of SIAH1 stabilizes TRIB3 and ameliorates OP. These findings provide a scientific basis and novel therapeutic target for regulating BMSCs differentiation and treating age‐related OP via the SIAH1–TRIB3 axis.